Differential Gene Expression of Checkpoint Markers and Cancer Markers in Mouse Models of Spontaneous Chronic Colitis

Author:

Ephraim Ramya1,Fraser Sarah1,Devereaux Jeannie1ORCID,Stavely Rhian2ORCID,Feehan Jack13ORCID,Eri Rajaraman4,Nurgali Kulmira156ORCID,Apostolopoulos Vasso13ORCID

Affiliation:

1. Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia

2. Pediatric Surgery Research Laboratories, Department of Pediatric Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

3. Immunology Program, Australian Institute of Musculoskeletal Science (AIMSS), Melbourne, VIC 3021, Australia

4. STEM/School of Science, RMIT University, Melbourne, VIC 3001, Australia

5. Department of Medicine Western Health, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, VIC 3010, Australia

6. Regenerative Medicine and Stem Cells Program, Australian Institute of Musculoskeletal Science (AIMSS), Melbourne, VIC 3021, Australia

Abstract

The presence of checkpoint markers in cancer cells aids in immune escape. The identification of checkpoint markers and early cancer markers is of utmost importance to gain clarity regarding the relationship between colitis and progressive inflammation leading to cancer. Herein, the gene expression levels of checkpoint makers, cancer-related pathways, and cancer genes in colon tissues of mouse models of chronic colitis (Winnie and Winnie-Prolapse mice) using next-generation sequencing are determined. Winnie mice are a result of a Muc2 missense mutation. The identification of such genes and their subsequent expression and role at the protein level would enable novel markers for the early diagnosis of cancer in IBD patients. The differentially expressed genes in the colonic transcriptome were analysed based on the Kyoto Encyclopedia of Genes and Genomes pathway. The expression of several oncogenes is associated with the severity of IBD, with Winnie-Prolapse mice expressing a large number of key genes associated with development of cancer. This research presents a number of new targets to evaluate for the development of biomarkers and therapeutics.

Funder

Senior Research Award from the Crohn’s & Colitis Foundation

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference115 articles.

1. Perspective: Cancer vaccines in the era of immune checkpoint blockade;Cebon;Mamm. Genome Off. J. Int. Mamm. Genome Soc.,2018

2. Checkpoint blockade in cancer immunotherapy;Korman;Adv. Immunol.,2006

3. Cellular Mucins: Targets for Immunotherapy;Apostolopoulos;Crit. Rev. Immunol.,2017

4. Cell-mediated immune responses to MUC1 fusion protein coupled to mannan;Apostolopoulos;Vaccine,1996

5. Dendritic cell immunotherapy: Clinical outcomes;Apostolopoulos;Clin. Transl. Immunol.,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3